Article Information
History
- June 7, 2020.
Article Versions
- Version 1 (June 5, 2020 - 22:00).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Theodoros V Giannouchos1, PhD,MS,
- Roberto A Sussman2,
- José Manuel Mier Odriozola, MD, PhD3,4,
- Konstantinos Poulas, PhD5 and
- Konstantinos Farsalinos, MD, MPH55,6,1
- 1Pharmacotherapy Outcomes Research Center, University of Utah, College of Pharmacy
- 2Instituto de Ciencias Nucleares, Universidad Nacional Autónoma de México, AP 70–543, Ciudad de México, CP 04510
- 3Clinica de Cáncer de Pulmón y Tumores del Tórax, Hospital Angeles Lomas, Hacienda de las Palmas. México
- 4Instituto de Cirugía Torácica Mínimamente Invasiva, Hospital Angeles Lomas, Hacienda de las Palmas. México
- 5Laboratory of Molecular Biology and Immunology, Department of Pharmacy, University of Patras, Greece
- 6Department of Public and Community Health, University of West Attica, Greece
- ↵1Corresponding author:
Konstantinos Farsalinos, MD, MPH Email: kfarsalinos{at}gmail.com
Posted June 07, 2020.
Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory–confirmed COVID-19 cases
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
13
Blogs/Media
Author Videos